# Encapsulation of the lipidated TLR7/8 agonist INI-4001 into ionic liposomes impacts H7 influenza antigen-specific immune responses

## TL;DR

Researchers found that encapsulating a TLR7/8 agonist in specific liposomes improves immune responses to an influenza antigen, with cationic and anionic liposomes showing distinct advantages in safety and effectiveness.

## Contribution

The study introduces a novel lipidated TLR7/8 agonist (INI-4001) encapsulated in liposomes, demonstrating how formulation characteristics influence vaccine immunogenicity and safety.

## Key findings

- Cationic DOPC/DC-Cholesterol liposomes showed low cytotoxicity and enhanced TNF-α production from human immune cells.
- Anionic DOPG/Cholesterol liposomes induced strong Th1 responses and high IgG titers after a single dose.
- Liposome formulation characteristics significantly impact the safety and immunogenicity of TLR7/8 agonist-adjuvanted vaccines.

## Abstract

Toll-like receptors (TLRs) are the best characterized family of Pattern Recognition Receptor-targeting adjuvants. Activation of TLR7/8 in particular, enhances antigen presentation by dendritic cells and macrophages, boosting Th1-mediated adaptive immune responses. However, poor pharmacokinetics and systemic toxicity of some TLR7/8 ligands hinder their clinical translation. Lipidation and incorporation of TLR7/8 ligands into liposomes can reduce systemic exposure, improve pharmacokinetics, pharmacodynamics, and presentation to immune cells. In the present study, a series of liposomal formulations incorporating a novel lipidated TLR7/8 agonist, INI-4001, were prepared to evaluate the effect of surface charge and lipid composition on the colloidal stability, cytotoxicity, innate immune activation, and adjuvant activity when combined with the recombinant Influenza A/Shanghai/1/13 (H7N9) Virus Hemagglutinin antigen (H7). The tested formulations include neutral (DOPC/Cholesterol), anionic (DOPG/Cholesterol), and cationic (DOPC/DC-Cholesterol, DOPC/GL67, DOEPC/Cholesterol, DOTAP/Cholesterol, or DOTAP + DDAB/Cholesterol) liposomes. These studies demonstrated that alongside the type and magnitude of particle surface charge, lipid composition was a determining factor in the regulation of immunogenicity and biocompatibility of INI-4001-loaded liposomes. Among the cationic liposomes evaluated, DOPC/DC-Cholesterol liposomes exhibited the lowest in vitro cytotoxicity while enhancing TNF-α induction from human peripheral blood mononuclear cells. Furthermore, murine immunization studies demonstrated that the same formulation enhanced H7-specific IgG titers and induced a Th1-polarized cell-mediated response compared to H7 antigen alone or the matched liposome lacking INI-4001. Of note, the anionic DOPG/Cholesterol INI-4001 liposomes induced a rapid response with significantly higher IgG titers after a single immunization and promoted strong Th1-polarized cellular responses, which may be advantageous in an influenza pandemic setting. These findings highlight the key role of liposome characteristics in optimizing the safety and immunogenicity of TLR7/8 agonist-adjuvanted subunit influenza vaccines.